Publications by authors named "Futian Ma"

Article Synopsis
  • - Atypical acute promyelocytic leukemia (aAPL) showcases a variety of complex retinoic acid receptor (RAR) fusion genes, including 31 rare RARA and RARG fusions, which differ from the well-known PML::RARA fusion.
  • - Some experimental bipartite X::RAR fusions show positive responses to all-trans retinoic acid (ATRA), unlike patients with ATRA resistance, prompting a deeper investigation into molecular mechanisms.
  • - The study identified novel tripartite fusion forms and significant differences in 3' splice patterns between RARA and RARG cases, suggesting transposable element involvement and highlighting the critical role of truncations in the ligand-binding domain that contribute to A
View Article and Find Full Text PDF

Objectives: This study aims to discuss the clinical manifestations and treatment of Familial hemophagocytic lymphohistiocytosis (FHL) caused by a mutation in the UNC13D gene.

Methods: A 6-year-old female child presented with unexplained febricity, splenomegaly, pancytopenia, hemophagocytic lymphohistiocytosis in bone marrow, decreased NK cell activity, soluble CD25 levels > 44000ng/ml. Genetic sequencing revealed a mutation in the UNC13D gene.

View Article and Find Full Text PDF
Article Synopsis
  • HLA-B*13:01:23 and HLA-B*13:01:01:01 are two different variants of the HLA-B gene.
  • The difference between these two variants is a single nucleotide change in exon 5.
  • This small genetic variation can potentially impact how the immune system functions.
View Article and Find Full Text PDF

Background: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency disorder caused by abnormal expression of the WAS protein (WASp) due to mutations in the WAS gene, and is generally characterized by microthrombocytopenia, eczema, recurrent infections, and high susceptibility to autoimmune complications and hematological malignancies.

Results: Herein, we identified a novel WAS mutation (c.158 T > C) using next-generation sequencing in a Chinese pedigree with WAS.

View Article and Find Full Text PDF

Ninety percent of relapse/refractory B-cell acute lymphatic leukemia (R/R B-ALL) patients can achieve complete remission (CR) after CD19-targeting chimeric antigen receptor T (CAR-T) cell therapy. However, around 50% of them relapse in 1 year. Persistent CAR-T cell engraftment is considered as the key to remain durable remission.

View Article and Find Full Text PDF

Background/aims: Acute and chronic leukemia are severe malignant cancers worldwide, and can occur in pediatric patients. Since bone marrow cell transplantation is seriously limited by the availability of the immune-paired donor sources, the therapy for pediatric leukemia (PL) remains challenging. Autophagy is essential for the regulation of cell survival in the harsh environment.

View Article and Find Full Text PDF

The purpose of the study was to assess the effect of the internal tandem duplication in FMS-like tyrosine kinase 3 (FLT3-ITD) on the outcome in pediatric acute myeloid leukemia (AML) patients. We identified eligible studies from several databases including PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) (from January 1995 to July 2015). Ten studies of 1661 pediatric patients with AML were included in exploring the relationship between the FLT3-ITD and overall survival (OS)/event free survival (EFS).

View Article and Find Full Text PDF

Here we investigated the establishment of multicenter cooperative treatment groups in China, as well as radiotherapy compliance and effectiveness among children with renal tumors. Medical records were reviewed for 316 children with renal tumors diagnosed by a multicenter cooperative group from 14 hospitals in China from 1998 to 2012. Median patient age was 29.

View Article and Find Full Text PDF

Objective: To study the expression and role of cyclic-AMP response binding protein (CREB) and Bcl-2 in children with acute leukemia.

Methods: Ninety-two children with acute leukemia (leukemia group) and 30 children with non-hematologic malignancies (control group) were enrolled. The mRNA and protein expression of CREB and Bcl-2 in bone marrow mononuclear cells were measured by reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot.

View Article and Find Full Text PDF